Roberto, M.; Astone, A.; Botticelli, A.; Carbognin, L.; Cassano, A.; D’Auria, G.; Fabbri, A.; Fabi, A.; Gamucci, T.; Krasniqi, E.;
et al. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers 2021, 13, 332.
https://doi.org/10.3390/cancers13020332
AMA Style
Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D’Auria G, Fabbri A, Fabi A, Gamucci T, Krasniqi E,
et al. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers. 2021; 13(2):332.
https://doi.org/10.3390/cancers13020332
Chicago/Turabian Style
Roberto, Michela, Antonio Astone, Andrea Botticelli, Luisa Carbognin, Alessandra Cassano, Giuliana D’Auria, Agnese Fabbri, Alessandra Fabi, Teresa Gamucci, Eriseld Krasniqi,
and et al. 2021. "CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives" Cancers 13, no. 2: 332.
https://doi.org/10.3390/cancers13020332
APA Style
Roberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D’Auria, G., Fabbri, A., Fabi, A., Gamucci, T., Krasniqi, E., Minelli, M., Orlandi, A., Pantano, F., Paris, I., Pizzuti, L., Portarena, I., Salesi, N., Scagnoli, S., Scavina, P.,
... Marchetti, P.
(2021). CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers, 13(2), 332.
https://doi.org/10.3390/cancers13020332
